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THE EFFICACY OF USING PLATELET RICH PLASMA IN TREATING 
CHRONIC TENDINOPATHIES 
MONIQUE GAINEY 
ABSTRACT 
As a common source of long-term pain and physical disability, overuse injuries, 
such as chronic tendinopathies, severely impact a patient’s quality of life. Caused by 
repetitive trauma, chronic tendinopathies affect hundreds of millions of people each year. 
The exact pathogenic mechanism in developing this musculoskeletal injury is still largely 
unknown, making clinical recommendations on the best course of treatment highly 
debatable. Nonetheless, advancements in biotechnology have made autologous blood 
products, specifically the use of platelet rich plasma injections, an increasingly popular 
method in the orthopedic field. Studies have shown that the concentrated platelet sample 
harbors a number of bioactive mediators. Once activated and injected at the site of injury, 
these growth factors and cytokines augment the natural healing process in tendinopathic 
cases. With limited reported complications, many clinicians believe that platelet rich 
plasma therapy is a safe and accessible treatment option for patients diagnosed with 
chronic tendinopathy. As such, the primary purpose of this paper is to determine the 
efficacy of platelet rich plasma injections in treating chronic tendinopathies.  
This literature review determined that current published studies and research on 
the effectiveness of PRP injections have produced contradictory results. Due to its 
autologous characteristic, platelet concentration differs significantly from patient to 
patient, contributing to high variability in terms of its effectiveness between patients. 
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However, with low long-term costs and fast recovery, PRP injections are a promising, 
non-surgical intervention for treating chronic tendinopathies. Several patient-centered 
clinical studies have reported significant improvements in range of motion and pain 
management when compared to traditional injection treatments. These effects are 
maximized when administered under ultrasound guidance or when used in conjunction 
with a strict eccentric exercise program. Nonetheless, continued research is needed to 
determine optimal injection standards so that clinical recommendations can be further 
developed and supported.  
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INTRODUCTION 
 
Musculoskeletal conditions have an enormous and growing impact worldwide. As 
a common cause of long-term pain and physical disability, musculoskeletal disorders 
impact a patient’s lifestyle, affecting their quality of life and contributing to their 
financial burden.1 Though the exact prevalence is unknown, overuse injuries account for 
approximately 30 to 50% of all musculoskeletal injuries and make up 30% of physician 
consultations.2–4 Affecting hundreds of millions of people each year, overuse injuries are 
caused by repetitive trauma. Encompassing both tendon rupture and inflammation, 
chronic tendinopathies are a common type of overuse injury.5 The exact pathogenic 
mechanism for developing a chronic tendinopathy is still largely unknown, and clinical 
recommendations on the best course of treatment are highly debatable. Currently, 
traditional management of chronic tendinopathies range from conservative physical 
therapy treatment to invasive surgical intervention.  
However, recent advancements in biotechnology have provided new avenues in 
treating chronic tendinopathies. Autologous blood products, specifically the use of 
platelet rich plasma injections, have become an increasingly popular method in the 
orthopedic field. Once activated, studies have revealed that the concentrated platelet 
sample releases a myriad of growth factors and cytokines at the site of injury. These 
bioactive mediators then augment the natural healing process and stimulate growth in 
chronic tendinopathic cases.6  
With limited reported complications, many clinicians believe that the platelet rich 
plasma therapy is a safe and accessible treatment option for patients. Nonetheless, current 
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literature and research on the efficacy of platelet rich plasma injections are not well 
established. Due to its unregulated use and lack of published procedural standards, 
differences in injection sample composition, methods of administration and blood 
product characteristics are prevalent.6 While many clinicians consider platelet rich 
plasma therapy ideal due to its autologous nature, such characteristics produces high 
variability in efficacy among individuals, in which the injection sample can vary as much 
as 50% between patients.7 Furthermore, the long-term effects of the released bioactive 
mediators on the surrounding tissue have yet to be clearly explained. 
As such, the primary purpose of this thesis is to determine the efficacy of platelet 
rich plasma injections in treating chronic tendinopathies. This paper will first provide 
relevant background information on chronic tendinopathies’ histology, pathology and 
healing mechanism. Next, current intervention treatments will be explored, highlighting 
limitations of those therapies. The paper will then describe the therapeutic efficacy and 
limitations of platelet rich plasma injections based on laboratory studies. Finally, a 
literature review evaluating published studies on the use of platelet rich plasma in treating 
tendon injuries will be presented in hopes that investigators can fill in potential gaps in 
research.  
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CHRONIC TENDINOPATHY 
Definition  
Tendinosis vs Tendinitis 
 Tendinopathy is defined as a disease of the tendon, referring to pain associated 
with tendon degeneration. This umbrella term encompasses a range of tendon disorders, 
including tendinosis, tendonitis and paratenonitis as summarized in Table 1 below.8,9 
Tendinosis, also known as chronic tendinopathy, is a failed healing response to tendon 
degeneration either from an untreated acute rupture or partial rupture that progressively 
worsens due to prolonged overuse. Chronic tendinopathies are characterized by a 
separation of collagen bundles, tendon rupture and absence of inflammatory signs.2,8,10,11 
Conversely, tendonitis, or acute tendinopathy, presents with the classic signs of an 
inflammatory response and can be treated relatively quickly with anti-inflammatory 
medications.12 Such signs include redness, swelling, pain and warmth. Paratenonitis 
refers to inflammation of the paratenon, a connective tissue sheath that surrounds the 
tendon fibers.12  
Tendinopathies were originally diagnosed as tendinitis, implying inflammation as 
a key component of the pathological process. However arthroscopic exploration reveal 
little to no inflammation at the injury site. Additionally, failed relief from anti-
inflammatory medications further confirmed this theory, suggesting that inflammation is 
not associated with all tendon injuries.9 Consequently, the terms tendinosis and tendinitis 
reflect such distinction, thus influencing clinical treatment options.  
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Table 1: Definitions of Tendinopathies. Different types of tendinopathies along with their 
distinguishing characteristics.3,12  
 
Tendon Histology 
 Tendon Composition & Function 
 Approximately 90% of a tendon’s cellular material is composed of tenocytes, the 
functional unit of a tendon.8,13 These elongated cells are mature forms of their precursors 
called tenoblasts. Tenoblasts are specialized versions of the main class of connective 
tissue cells called fibroblasts. Tenoblasts are highly mobile, proliferative cells stimulated 
by mechanical load or after injury.8,9 The spindle-shaped, immature tenocytes are 
arranged in parallel rows along collagen fibers and contribute to the surrounding 
extracellular matrix by producing collagen, elastin and ground substance. Other cells 
found within tendons include chondrocytes, synovial cells and endothelial cells.8 Also a 
derivative of fibroblasts, chondrocytes are cartilage cells primarily located at the insertion 
site, where the tendon meets the bone. Synovial cells can be found within a tendon 
•Definition: non-inflammatory tendon degeneration
•Clinical Signs: palpable tendon nodule, tenderness, 
prolonged pain
•Prevalence: common
•Recovery Time: 3 - 6 months
Tendinosis
(chronic
tendinopathy)
•Definition: tendon degeneration with inflammation
•Clinical signs: hematoma, atrophy, inflammatory 
cells, immediate pain, warmth, tenderness, swelling
•Prevalence: uncommon
•Recovery time: 4 - 6 weeks
Tenonitis
(acute tendinopathy)
•Definition: inflammation of the paratenon
•Clinical signs: inflammation, swelling, pain, 
crepitation, local tenderness, warmth, dysfunction
•Recovery time: 4 - 6 weeks
Paratenonitis
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sheath, providing lubrication to a joint. Though limited in number within a tendon, 
endothelial cells are located along the inner lining of blood vessels. 
The extracellular matrix that surround tenocytes and tenoblasts is primarily 
composed of ground substance and collagen, 68% and 30% respectively, with elastin 
making up the last 2%.12 Glycosaminoglycans, glycoproteins, proteoglycans and water 
are found within a tendon’s ground substance. These molecules diffuse nutrients and 
gases to the area and provide structural support, allowing the collagenous proteins to 
form a fibril shape.8,9,12,13 The most common type of collagen found within a tendon is 
Type I collagen, which gives tendons its tensile strength. Type III, Type V and Type XII 
collagen are also present within tendons. Type III collagen produces smaller, less 
organized fibrils and aids tendons in healing and development processes. Type V 
collagen can be found within the core of a fibril, modulating its growth. Type XII 
collagen provides further structural support by binding to proteoglycans and fibromodulin 
found within the extracellular matrix. Elastin gives tendons its elastic properties, 
promoting flexibility.8,12,13 
Tendon Structure  
As illustrated in Figure 1 below, a tendon is formed in a highly organized manner. 
Collagen, produced by tenoblasts, aggregates to form tropocollagen, which is composed 
of three polypeptide strands. This helical structure is then arranged in parallel rows to 
form a tendon fibril, the basic structural unit of a tendon. A group of fibrils group 
together to form tendon fibers which make up a tendon fascicle.12 Fibers are surrounded 
by a sheath called the endotenon. This matrix of loose, areolar connective tissue carries 
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blood vessels, lymphatics and nerves throughout the tendon and permits movement 
between individual fibers.3,8,12,13 Fascicles are grouped together by an outer connective 
called the epitenon. The paratenon is the outermost sheath of a tendon. Between the 
paratenon and the epitenon is a fluid rich peritendinous area, which provides lubrication 
for protection and reduces friction.8,12  
	  
 
Figure 1: Hierarchical Organization of a Tendon. The structural unit of tendon is a 
collagen fibril, several of which form a fiber. A bundle of fibers form a fascicle which 
group together to form a tendon.14 
 
Tendons are metabolically active tissue, as such a continuous blood supply is 
required for its survival. The vasculature within a tendon varies depending on the 
tendon’s function and location. Furthermore, its blood supply can be inhibited by friction, 
compression or wear.12 Compared to skeletal muscle, the metabolic rate of tendons is 
lower, consuming 7.5 times less oxygen than muscle. Furthermore, tenocyte turnover rate 
is approximately 100 days.8 Due to this relatively low metabolic and slow turnover rate, 
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tendons are considered to be hypovascular. As such, these areas have high concentrations 
of endostatin, an endogenous angiogenic inhibiting factor.8 Tendon’s blood supply 
network is found in the endotenon and at two major junctions – the musculotendinous 
and osteotendinous junctions.13 The musculotendinous junction, which runs along the 
length of the tendon between the muscle and tendon, is rich in nerve receptors and 
sustains great mechanical stress. The osteotendinous junction, located between the bone 
and tendon is the most common site of overuse tendon injuries.3,8,12  
 Tendons have a vast array of nerve cells both within and on their surface, with 
most of the innervation provided by nerves from surrounding muscles and skin. The 
location and number of these cells varies according to the tendon’s function. Each of 
these cells convert stimuli into an afferent nervous signals, sending specific information 
to the central nervous system.8 The types of nerve cells that can be found in and around 
tendons include Ruffini corpuscles, Pacinian corpuscles, Golgi tendon organs and free 
nerve endings as summarized in Table 2 below. Ruffini corpuscles are low threshold 
mechanoreceptors that slowly respond to changes position and stretch. Pacinian 
corpuscles are sensitive mechanoreceptors that adapt quickly to sudden changes such as 
velocity. Golgi tendon organs are the most abundant mechanoreceptors found within a 
tendon. These nerve cells, located along muscle spindles, detect changes in both pressure 
and stretch within muscles and can inhibit muscle contraction. As with many soft tissue 
throughout the body, tendons contain nociceptors called free nerve endings, which are 
found inside the tendon within the peritendinous region.8,13  
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Table 2: Tendon Nerve Cells. The nerve cells found within or around tendons include 
Ruffini corpuscles, Pacinian corpuscles, Golgi tendon organ and free nerve cells. Their 
corresponding functions are summarized below.8 
 
Function  
 The primary function of tendons is to connect muscle to bone, transmitting forces 
from muscle to bone and aiding in movement.15 Similar to other tissues throughout the 
body, tendons are designed according to their functional demands. As such, each tendon 
has differences in its structure, composition, metabolism and cell turnover. Therefore, the 
mechanical behavior depends on its structure and composition with the size and number 
of the tendon fibers determine the load a tendon can withstand. For instance, the 
metabolic activity and cell turnover for a tendon is high if it is subject to high stress. 
Additionally, tendons with a larger cross sectional area have the ability to withstand 
larger loads, while tendons with longer fibers have a greater capacity to elongate.8,12 
Pathogenesis  
Histopathology 
Compared to a normal tendon which is brilliant white, firm and has a fibroelastic 
texture, a degenerative tendon is thin, fragile and disorganized with a grey, yellow 
Ruffini 
Corpuscles
•Mechanoreceptor
•Slow adapting
•Respond to 
changes in 
position, pressure 
and stretch
Pacinian 
Corpuscles
•Mechanoreceptor
•Quick adapting
•Respond to 
sudden changes 
in vibration and 
pressure
Golgi Tendon 
Organ 
•Mechanoreceptor
•Respond slowly 
to changes in 
pressure and 
stretch  
Free Nerve 
Cells
•Nociceptors: 
respond to pain
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color.2,16 Macroscopically, intratendinous regions of the tendon are poorly defined rather 
than a regular, uniform and densely organized shape, as illustrated in Figure 2 below. 
Collagen fibers separate from each other creating irregular waves and loss of transverse 
bands. Resembling the appearance of mucus, pathologists define this disorganized, soft, 
yellow tissue as mucoid degeneration. Conversely, if the degenerative tissue is hard 
rather than soft, it is described as hyaline, or glassy.17 Evaluation of injured tendons 
reveals degenerative transformations in 90% of biopsies performed.8 Hyaline or mucoid 
degenerations, fibrocartilaginous metaplasia, calcium hydroxyapatite deposits and 
hypoxic changes in tenocytes are hallmark components of degenerative changes in 
tendons.8,13,16 In contrast to the traditionally avascular environment, hypervascularity is 
also prevalent. Pain is associated with nerve growth and increased vasculature.16,18 A 
degenerative tendon is also characterized by lack of inflammatory cells, such as 
macrophages, neutrophils and other inflammatory mediators. Tenocytes, which normally 
have a spindle shape, appear to have a prominent rounded, pyknotic nuclei, suggesting a 
higher rate of apoptosis.2,8,13,16 Normal tendons are composed of Type I collagen; 
however, degenerative tendons have an abnormal amount of Type III collagen produced 
by tenocytes. Compared to Type I collagen, Type III collagen is structurally deficient in 
cross links, creating a weakened tendon more prone to rupture. Tendolipomatosis is also 
present in tendinopathic cases, in which degraded Type I collagen fibers are replaced by 
lipid cells. The high proteoglycan turnover produces a robust matrix and high 
concentrations of proteins in the ground substance.2,8,13,16,19  
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Figure 2: Normal Tendon versus Degenerative Tendon. These photos highlight the 
physical changes that occur in tendon degeneration. Compared to a normal tendon, a 
degenerative tendon exhibits loss of structural organization with irregular, loosely formed 
fibers.20 
Biomechanics Behind Tendon Pathogenesis 
Without elastic properties, tendons follow the traditional stress-strain curve. However, 
elastin fibers make up 2% of tendons, allowing tendons to elongate by 70% of their 
original length.8 As illustrated in the Figure 3 below, at rest collagen fibrils are arranged 
in a wavy configuration, contributing to a tendon’s shock absorbing property. Once the 
tendon is strained 2% beyond its resting length, the collagen fibers stretch according to 
the increasing load, forming a linear configuration. A tendon will return to its original 
configuration once the load is removed, but only if the fibers are not stretched beyond 4% 
its original length. Beyond that point, the collagen fibers slide past one another and the 
intermolecular collagen cross-links fail, causing microscopic rupture within the fibers. At 
8% of elongation, tensile failure of the fiber occurs, and the tendon has ruptured.8,12  
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Figure 3: Stress versus Strain Graph. This figure illustrates the biomechanics of internal 
tendon degeneration, highlighting the physical changes in tendon fibers with increasing 
applied stress.21 
Pathogenic Mechanism 
Chronic tendinopathies develop as a result of repeated injury or damage to a 
tendon over an extended period of time. Though the exact mechanism is still unknown, 
researchers believe that tendon inflammation and degeneration are not mutually exclusive 
events, but work simultaneously in the pathogenesis of tendinopathies. Tendinopathies 
are believed to develop as a result of overloading a tendon, causing collagen fibers to 
slide past each other and weakening the collagen cross-links. Microruptures, as described 
above, initiate a pathological response, recruiting inflammatory cells and increasing the 
production of growth factors, cytokines and free radicals. Continued microruptures 
contribute to tissue degeneration by impairing metabolic activity, which progressively 
decreases elasticity and tensile strength. Tendons are especially susceptible to rupture due 
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to its poor vascularity, increasing the risk for further injury and prolonging recovery.8,22 
As diagramed in Figure 4, repetitive tendon microruptures due to excessive strain and 
overuse eventually leads to a macroruptured tendon, in which patients present with 
symptomatic signs of a chronic tendinopathy.8 
 
Figure 4: Proposed Mechanism for the Development of Chronic Tendinopathy. 
Repetitive stress leads to microruptures within a tendon. Continuously overloading a 
tendon leads to development of a macrorupture, in which patients exhibit decreased 
function and pain at the site of injury.8 
Tendon Healing 
 
Factors that Influence Healing  
There are numerous of factors that influence healing once a rupture of a tendon 
occurs. The principal mediators in healing include cytokines, matrix metalloproteinases, 
growth factors and nitric oxide. When a tendon ruptures, these essential factors are 
overexpressed, playing a unique, critical role in wound healing.  
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Cytokines regulate inflammatory and apoptotic pathways, augmenting the 
reparative process. They are involved in the regulation of matrix turnover in 
tendinopathies. Cytokines are released in response to a specific type of cytokine called 
interleukin-17A (IL-17A). As a pro-inflammatory cellular mediator, IL-17A induces 
various biological processes. More specifically, IL-17A activate fibroblasts, macrophages 
and endothelial cells to produce chemokines, nitric oxide synthase, matrix 
metalloproteinases and other cytokines.8,23  
Healing is also mediated by matrix metalloproteinases (MMP) and their tissue 
inhibitors (TIMPs). As regulators of extracellular matrix degradation, MMPs are a key 
component in the pathological process with heightened levels during a tendinopathy. 
Each type of MMP has unique roles in matrix remodeling. MMP-9 and MMP-13 
participate in collagen degradation, while MMP-2, MMP-3 and MMP-14 are involved in 
collagen degradation and remodeling.8,16  
Growth factors are essential to wound healing, playing a critical role in the 
inflammatory and proliferative phases of wound healing. Secreted as mature peptides 
from a platelet’s alpha granules, growth factors induce proliferation and migration of 
tenoblasts to the site of injury. There are several growth factors that are involved in the 
pathological process of a tendinopathy, each carrying out a specific function. Platelet 
derived growth factors (PDGF), transforming growth factor (TGF- β), fibroblast growth 
factor (FGF), vascular endothelial growth factor (VEGF) and scleraxis (Scx) are the most 
common growth factors found in tendon healing. PDGF aids in the activation and 
recruitment of macrophages and tenoblasts. TGF-β induces tenoblast mitogenesis, 
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enhancing extracellular matrix development. Following a tendon macrorupture, the 
hypoxic environment stimulates the production of hypoxia inducible factor leading to an 
increased expression of VEGF. VEGF, along with a cytokine called angiopoietin, 
promotes angiogenesis via the upregulation of MMP and downregulation of TIMP-3. Scx 
is a marker of tendon morphogenesis and can induce neovascularization. FGF modulates 
of various steps in tendon healing, including angiogenesis and cell migration. Table 3 
below summarizes the above critical growth factors involved tendinopathies along with 
their corresponding function.8  
Nitric oxide (NO) is a free radical that induces apoptosis in inflammatory cells. 
Synthesized by nitric oxide synthases (NOS) in response to VEGF, NO carries out 
various roles throughout the reparative process. Not only does this molecule increase 
collagen synthesis, it also promotes angiogenesis and causes vasodilation, recruiting more 
mediators to the site of injury. NO also stimulates fibroblast proliferation and the 
synthesis of MMPs.8  
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Table 3: Growth Factors. Summary of growth factors released by platelets along with 
their unique functions.6,24  
 
 
Transforming Growth Factor-β (TGF-β)
•Stimulates undifferentiated tenoblast proliferation & chemotaxis, angiogenesis,
•Regulates cell mitogenesis, collagen synthesis
•Inhibits macrophage and lymphocyte proliferation, osteoclast formation
Fibroblast Growth Factor (FGF)
•Promote growth and differentiation of chondrocytes and osteoblasts
Platelet-Derived Growth Factor (PDGF)
•Macrophage activation, angiogenesis, tenoblast chemotaxis and proliferation, 
•Enhance collagen synthesis, 
•Enhance osteoblast proliferation
Epidermal Growth Factors (EGF)
•Stimulates endothelial chemotaxis & differentiation 
•Stimulates angiogenesis
•Regulates collagen secretion, 
•Stimulates mesenchymal mitogenesis
Vascular Endothelial Factor (VEGF)
•Increases angiogenesis and vessel permeability
•Vasodilation
•Stimulates mitogenesis of endothelial cells
Connective Tissue Growth Factor (CTGF)
•Promotes angiogenesis, cartilage regeneration, fibrosis and platelet adhesion
Insulin-Like Growth Factor (IGF)
•Chemotactic for fibroblasts and stimulates protein synthesis, enhances bone 
formation
Platelet Derived Angiogenic Factor (PDAF)
•Induces vascularization via stimulating vascular endothelial cells
Interleukin-8 (IL-8)
•Pro-inflammatory mediator, recruit inflammatory cells
Keratinocyte Growth Factor (KGF)
•Promote wound healing by stimulating endothelial cells growth, migration, adhesion 
and angiogenesis
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Healing Mechanism 
Tendon healing occurs in distinct three phases: acute inflammatory phase, 
proliferation phase, and the remodeling and maturation phase. The acute inflammatory 
phase begins approximately 3 to 7 days after injury.8 This phase is characterized by 
release of vasoactive and chemotactic factors, promoting angiogenesis, increasing blood 
flow and allowing inflammatory cells to be recruited to the area.6,22 Monocytes, 
neutrophils and macrophages phagocytose necrotic debris. Once activated, platelets 
release growth factors from their alpha granules allowing pluripotent cells to differentiate 
to tenoblasts. Tenoblasts begin the rebuild process by producing Type III 
collagen.6,8,10,13,22  
 The proliferation phase lasts approximately 5 to 21 days and is marked by peaked 
collagen synthesis. Chemotactic factors recruit more tenoblasts to the site of injury and 
production of Type III collagen continues at elevated rates, increasing mechanical and 
tensile strength of the tendon.6,8,10,13,22 Collagen fibrillogenesis, or formation of collagen 
fibrils, is distinguished into three phases. First, collagen molecules assemble to form 
immature fibrils. This is followed by linear growth, in which collagen molecules add to 
the ends of the newly formed fibrils. The longest and final phase of fibrillogenesis is 
lateral growth, increasing the fibrils diameter.8 Mitogenic and angiogenic growth factors 
stimulate neovascularization. Concentrations of glycosaminoglycan, fibronectin and 
proteoglycan remain high in the surrounding ground substance, creating a more robust 
matrix and increasing the tensile strength.13  
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 The remodeling and maturation phase begins approximately 6 to 10 weeks after 
incidence of injury and can continue for up to a year. The remodeling phase is 
characterized by a reshaping and resizing of tendon structure. The affected tissue changes 
from cellular to fibrous with collagen fibers aligning in the direction of stress. 
Glycosaminoglycan and Type III collagen synthesis is decreased with Type I collagen 
replacing the weaker Type III. Due to Type I collagen’s robust cross-links, this exchange 
increases tendon strength. The maturation phase is marked by is characterized by the 
prevalence of fibrous tissue and formation of scar-like tissue.10,13,22 Table 4 below 
highlights the key characteristics of each phase of tendon healing. 
 Abnormal healing during any phase can compromise the quality of a tendon. 
Tissue quality is also affected by a hypoxic environment, growth factor imbalance and 
infection as well as the patient’s metabolic and nutritional status.6  
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Table 4: Summary of Tendon Healing Mechanism. Tendons have 3 phases of healing: 
acute inflammatory, proliferation and remodeling and maturation phase. Each are 
characterized by unique histological changes as outlined in the diagram.10,13,20 
 
 
Clinical Symptoms 
Tendinopathies are clinically diagnosed depending on the duration of symptoms, 
as demonstrated in Figure 5 below. Patients are diagnosed with acute tendinopathy if 
symptoms present for 0 to 6 weeks, subacute tendinopathy if symptoms persist for 6 to 12 
weeks and chronic tendinopathy if longer than 3 months.2 Patients present with pain, 
swelling and localized stiffness at the site of injury that usually coincides with increased 
activity.2,3,8,18 Patients describe the pain as sharp or stabbing during normal activity and 
dull, achy at rest. Diagnosis is confirmed with physical manipulation to stimulate tendon 
stress and reproduce patient’s pain.3 Pain may ease while exercising; however, with 
continued activity, pain worsens and limits function and range of motion. Ultrasound 
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imaging reveal tendon thickening and increased blood flow and water content.13,18 In 
some cases, chronic tendinopathies may develop asymptomatically; however, symptoms 
usually present at the time of nerve proliferation.8 
The most common tendinopathies occur in locations of repetitive use, especially 
among athletes. These areas include the rotator cuff, biceps brachii tendon in the 
shoulder, patella tendon, Achilles tendon and tibialis posterior tendon in the ankle and 
foot and medial and lateral epicondyles of the elbow. Golfer’s elbow is a tendinopathy of 
the pronator teres and flexor carpi radialis tendons in the forearm. Jumper’s knee is 
tendinopathy at the proximal end of the patellar tendon. This injury is prevalent in 
athletes who play basketball, volleyball, tennis and soccer. Achilles tendinopathy is a 
tendinopathy of the Achilles tendon, which is formed by the gastrocnemius and soleus 
muscles in the lower leg.8  
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Figure 5: Overall Progression of Chronic Tendinopathy. Patients present with clinical 
symptoms after repetitive stress and when a tendon is said to have failed at healing.18 
Risk Factors 
 
Intrinsic Factors 
There are several intrinsic factors that make people more susceptible for 
developing a tendinopathy. Co-morbidities are a significant risk factor, especially those 
that influence the body’s microvasculature. Hypertension is statistically associated with 
tendinopathies in women, while men under the age of 44 diagnosed with diabetes are at 
greater risk for developing chronic tendinopathy. Other diseases associated with 
tendinopathies include obesity, systemic diseases, neurological conditions, infectious 
diseases, chronic renal failure and systemic lupus erythematosus. A person’s genetic 
background also influences their likelihood of developing a tendinopathy. Variations 
within Type V collagen and tenascin C gene sequences have been linked to chronic 
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tendinopathies. Due to a reduction of arterial blood flow and impaired metabolism, 
tendinopathy is prevalent in patients over 70 years old.8  
Extrinsic Factors 
Extrinsic factors involved in chronic tendinopathies include overuse injuries 
especially in sport or training activities. Having a prior injury that has not fully healed 
also increases the likelihood of developing a tendinopathy. Using improper footwear or 
equipment, traumatic events and environmental conditions, specifically training in cold 
weather, may also contribute to the incidence of chronic tendinopathies. Medications, 
including hormone replacement therapy and oral contraceptives, are linked to tendon 
weakening. Antibiotics that contain fluoroquinolone, such as levofloxacin, ofloxacin, 
norfloxacin, ciprofloxacin and pefloxacin, are often used to treat respiratory infections. 
However, fluoroquinolone has been shown to induce tendon cell death, cause oxidative 
damages and collagenolysis further weakening the structure of a tendon.8,25  
 
Figure 6: Risk Factors. Overview of risk factors for developing chronic tendinopathy. 8 
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Current Interventions 
 
Oral Analgesics: NSAIDS 
There is currently no consensus on the best treatment for chronic tendinopathies. 
Nonsteroidal anti-inflammatory drugs (NSAIDS) are generally prescribed to patients 
diagnosed with a tendinopathy in order to relieve pain. Though NSAIDS are successful in 
treating tendinitis, or acute tendinopathies, histopathological analysis of chronic cases 
reveal a lack of an inflammatory response.11 Studies have shown that NSAIDS may 
inhibit cell migration and proliferation thereby impairing tendon healing.26 Prescribing 
NSAIDS is a treatment option for managing pain within two weeks of incidence; 
however, little evidence supports its use in chronic tendinopathic cases.11,27 Additionally, 
prolonged use of NSAIDS increases a patient’s risk of gastrointestinal, cardiovascular 
and renal disorders.2 
Eccentric Exercise 
 Considered to be the most effective treatment option, performing eccentric 
exercises is the first line recommendation for patients diagnosed with chronic 
tendinopathy.11,28 Training regimens are tailored to each patient’s individual needs after 
initial assessment. Exercises focus on slowly lengthening muscle fibers and loading the 
tendon, improving function and gradually restoring tissue integrity. Performing such 
repetitive movements promotes mechanotransduction, allowing cells to convert a 
mechanical stimulus into a cellular response. This process triggers structural changes 
within a tendon, increasing tenoblasts’ metabolic rate thereby producing collagen.2,3,12,27 
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Braces may also be used to reinforce and protect tendons during exercises so that the 
affected tendon is gradually strengthen.29  
Extracorporeal Shock Wave Therapy 
 Extracorporeal shock wave therapy (ESWT) is a technique that uses acoustic 
shock waves to promote structural changes within tendons.29 ESWT is seen as a second 
line alternative to surgery after eccentric training has failed.11,28 Its efficacy has yet to be 
determined; however, clinicians believe that shock waves disrupts unmyelinated nerve 
fibers and remove damaged cells, allowing tendons to regenerate. Though the exact 
mechanism is still unknown, the objective of ESWT is to stimulate cell activity and 
increase blood flow, promoting tendon healing.2,26,29  
Therapeutic Ultrasonography 
Therapeutic ultrasonography administers high frequency vibrations to the injured 
tendon, generating heat that penetrate superficial tissue. Research has shown that 
therapeutic ultrasonography reduces swelling, relieve pain and increase the rate of 
collagen synthesis by stimulating tenoblast proliferation. Similar to ESWT, therapeutic 
ultrasonography is seen as a second line alternative to surgery after eccentric training has 
failed though its clinical effectiveness remains questionable.11,26 
Injection Therapy: Sclerosing Injection  
 Sclerosing agents are injected into the site of injury in order to promote tendon 
repair. Sclerosing agents harden surrounding vessels and nerves, stimulating 
neovascularization and eliminating pain associated with tendinopathies.2,29 A sclerosing 
agent, such as polidocanol, is often administered under ultrasound guidance, allowing the 
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medication to be precisely administered. Research suggests that this treatment option has 
mixed efficacy and can lead to complications such as thrombosis.26  
Injection Therapy: Steroid Injection  
 Corticosteroid injections are the most common treatment administered to patients 
with chronic tendinopathies.18 Usually performed under ultrasound guidance, 
corticosteroids reduce pain and swelling at the site of injury. However, these steroidal 
injections are not effective in providing long term relief for chronic tendinopathies. 
Though they have anti-inflammatory and immunosuppressive properties, corticosteroids 
only provide temporary relief, and pain recurrence is common.2,28 Additionally, many of 
the reported side effects of corticosteroid injections, including limiting tenocyte 
proliferation, vasoconstriction and decreasing collagen production, inhibit tendon 
healing.11,26  
Surgery 
 Surgery is usually the last resort option for patients suffering from chronic 
tendinopathy when other treatments have failed. Overall, the goal of tendon surgery is to 
remove degenerative tissue and stimulate tendon healing.26 There are two types of 
surgeries that can be performed – open or arthroscopic. Depending on the severity of the 
tendinopathy, open surgery may involve tenotomy, where a surgeon cuts the tendon, or 
simply a removal of abnormal tissue or debris.10,29 Conversely, arthroscopic surgery is a 
minimally invasive procedure that allows physicians to visualize, accurately diagnose and 
treat a tendinopathy. Similar to open surgery, surgeons can remove abnormal tissue using 
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arthroscopic techniques.29 Arthroscopic procedures have proven to be as effective as open 
surgery.28  
Table 5: Treatment Options. Summary of chronic tendinopathy treatment options.3,29 
 
PLATELET RICH PLASMA 
Background 
 
After discovering that platelets harbor numerous amounts of growth factors and 
cytokines, investigators hypothesized that platelets could augment and even accelerate 
tissue healing.7,30 Consequently, the platelet rich plasma (PRP) technique was developed 
and first used in 1987 during an open heart surgery.24,30 The rationale behind the use PRP 
is to enhance the body’s reparative and regenerative processes by promoting matrix 
synthesis and healing at the site of degeneration.2,24,26,29 In addition to releasing growth 
factors at the site of injury, researchers theorize that PRP increases the expression of 
Type I collagen and Type III collagen and synthesis of the extracellular matrix.26,31,32 
PRP injections have become increasingly popular in the dental and plastic surgery fields 
in an attempt to accelerate wound healing. This technique is now prevalent in the 
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orthopedics field, providing patients with a non-operative option to potentially assist in 
the healing and remodeling of musculoskeletal injuries.24 
Definition 
 
PRP is defined as a portion of plasma that has a platelet count above the baseline 
of whole blood.6,7,24 The composition of PRP depends on the concentration of platelets, 
amount of red blood cells and the presence or absence of white blood cells. Hence, a PRP 
sample varies from patient to patient.7 PRP encompasses all types of platelet concentrates 
regardless of the sample’s exact composition. For example, this umbrella term includes 
leukocyte-platelet rich plasma (L-PRP), leukocyte-platelet poor plasma (L-PPP), pure-
platelet rich plasma (P-PRP) or pure-platelet poor plasma (P-PPP). Leukocytes, also 
known as white blood cells, are immune cells that protect the body from foreign 
pathogens. Some preparation techniques take advantage of these cell’s immune properties 
and include them in the injection sample.30 
Platelet Physiology and Function  
 
 Platelets make up 6% of blood with red blood cells and white blood cells making 
up 93% and 1% respectively.24 Platelets are small, irregularly shaped, anucleated cells 
derived a megakaryocyte precursor.6,7,24 The normal platelet count for a healthy adult is 
between 150,000 to 450,000 cells per microliter of blood.24 With a life span of 
approximately 7 to 10 days, platelets circulate throughout the body expressing 
glycoproteins on their surface.6,24 Platelets have a vital role in hemostasis, aiding in 
wound healing, coagulation, inflammation, angiogenesis and antibacterial defense.6,7 
With over 1,000 proteins, platelets act as a natural reservoir for growth factors. These 
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mediators are involved in numerous biological processes including mitogenesis, 
chemotaxis, differentiation and metabolism.6,7,30 Once activated following an injury, 
platelets aggregate together and release their granules to stimulate an inflammatory 
cascade and wound healing. Platelets are composed of alpha and dense granules. Dense 
granules contain various neurotransmitters, inorganic molecules and coenzymes such as 
serotonin and adenosine triphosphate. Conversely, growth factors reside within a 
platelet’s alpha granule.33 As previously mentioned above and summarized in Table 3, 
some of the essential growth factors present in platelets include platelet derived growth 
factor, insulin-like growth factor, vascular endothelial growth factors, epidermal growth 
factor and fibroblast growth factor.24,34 
Plasma 
Plasma is the fluid part of blood. It contains numerous ions, inorganic and organic 
molecules that are critical for numerous biological processes. Plasma also contains a 
protein called fibrinogen in addition to other clotting factors. When these biological 
mediators are exposed to thrombin, the clotting cascade is initiated.7 
Platelet Rich Plasma Preparation  
 
PRP injections are a simple, non-invasive procedure. First, blood is taken from a 
patient’s peripheral vein. Anticoagulants, such as citrate dextrose-A or citrate phosphate 
dextrose, are added to the sample, hindering the normal clotting cascade and allowing 
time between the extraction to the injection points.7 Next, the blood sample is centrifuged 
in order to separate its components. Lasting approximately 5 to 20 minutes, the 
centrifugation process occurs in two steps in order to thoroughly fractionate the blood 
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and concentrate the platelets.2,6,24 The first centrifugation step, or soft spin, occurs at a 
low speed and separates the platelets from the red blood cells and white blood cells, 
leaving the platelets suspended in the supernatant. Once the red blood cell layer is 
extracted, the hard spin further concentrates the platelets into platelet poor and platelet 
rich fractions. After centrifugation, the platelet rich sample is extracted and is activated 
by the addition of thrombin or calcium chloride.24,35 Within the first 10 minutes of 
activation, 70% of the platelet growth factors are secreted from their alpha and dense 
granules.7,36 The platelet rich sample is immediately re-injected at the site of injury, 
sometimes under the guidance of an ultrasound for increased precision.6 The injection 
sample can be prepared in a variety of ways. For instance, some techniques take 
advantage of the immune properties of white blood cells and include them in the injection 
sample. Additionally, platelet rich plasma may be injected to the site of injury with or 
without activation and is often applied as a gel during open surgery.7,30,37,38  
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Figure 7: Overview of PRP Preparation. After extraction from the individual, blood 
sample undergoes a soft spin, producing a three layers: plasma (55%), buffy coat (1%) 
and red blood cell (45%). The platelets reside in the buffy coat layer along with white 
blood cells. Once the red blood cells are extracted from the sample, a hard spin is 
performed to further separate the components of the sample, creating a platelet pellet at 
the bottom of the test tube. The pellet is combined with the plasma to create PRP.7 
 
Theory Behind Centrifugation  
 The centrifugation procedure takes advantage of gravitational forces in order to 
separate molecules of varying mass. This separation is based on Stoke’s Law, which 
states that the settling velocity of a molecule is proportional to their radius.7 A particle 
with a larger molecular weight, and consequently larger radius, will settle faster than 
those with a lower molecular weight. Hence, platelets, which are twice as small as red 
blood cells, will settle slower and remain in the supernatant, or the liquid portion of the 
sample.7 For greater efficacy, platelets should be concentrated between four and six times 
the sample’s baseline concentration.24 
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Efficacy of Platelet Rich Plasma  
Several in vitro and in vivo studies have been conducted to determine exactly 
what effect PRP injections have in tendon healing. As such, experiments have attempted 
to measure the expression of growth factors in order to determine if these mediators 
influence the healing mechanism of tendons. In 2002, Taylor and colleagues injected 
platelet rich blood in rabbits with patellar tendinosis and compared mechanical properties 
at varying time points after injection. By Week 12, the treatment group had a significant 
increase in range of motion and was able to withstand larger tendon loads before failure, 
suggesting platelet injections improves mechanical strength. Furthermore, histological 
analysis at 6 and 12 weeks post-injection revealed a stronger angiogenic response.39 A 
laboratory animal control study by Lyras et al determined the effect PRP has on the 
expression of insulin-like growth factor-1 (IGF-1) in the healing process of a patellar 
tendinopathy. Compared to the control group, the treatment group not only healed faster 
but also expressed high levels of IGF-1, a known mediator in tenoblast recruitment and 
protein synthesis. Based on these findings, researchers concluded that PRP gel may 
improve tendon healing due to the overexpression of IGF-1.40,41 In a similar study, 
Schnabel and colleagues examined gene expression patterns, collagen content and DNA 
in cultured degenerative tendon cells. In cultures with the PRP media, investigators found 
enhanced expression of collagen molecules including Type I and Type III collagen; 
however, no increased expression of the catabolic molecules MMP-3 and MMP-13 were 
observed.42  
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Poor vascularity of tendons hinders their healing capacity; however, in vitro 
studies focusing on angiogenic effect of PRP suggests this treatment option may offset 
such limitation. A study performed by Lyras and colleagues, attempted to assess the 
effect platelet rich plasma has on angiogenesis during tendon healing. Using rabbits 
diagnosed with Achilles tendinopathy, investigators injected PRP into the PRP treatment 
group comparing its outcome to the saline control group. Over the course of the study, 
researchers observed significantly more vessel formation in the PRP group compared to 
the control and a shortened healing time. As such investigators concluded that PRP 
injections enhance angiogenesis and accelerates the healing process.43 In 2007, Anitua et 
al evaluated the effect PRP proteins had on tendon healing. The growth factors measured 
during the study included PDGF, TGF-B1, IGF-1, hepatocyte growth factor (HGF), 
VEGF and EGF. Researchers found higher levels of VEGF, IGF-1, PDGF and TGF-B1 
in the PRP tendon cell sample. Based on their biological function, the overexpression of 
these growth factors suggests that these mediators may aid in the healing process through 
the induction of cell proliferation and synthesis of angiogenic factors.44 
An in vitro study conducted by de Mos and colleagues suggests that PRP 
injections may accelerate tendon healing by inducing cell proliferation and collagen 
production. Using cultured human tenocytes, de Mos et al compared the effects PRP 
medium had on the expression of growth factors and collagen production. Investigators 
cultured human tenocytes in varying concentrations of PRP with platelet number 
increasing to 2.55 times the baseline concentration. The study revealed that tenocytes 
exhibited increased cell proliferation rates and total collagen production in the medium 
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containing PRP. Additionally, the PRP samples had increased expression of growth 
factors, VEGF and TGF-B1, as well as matrix degrading enzymes, MMP-1 and MMP-3. 
Due to the higher prevalence of these growth factors and enzymes, researchers concluded 
that PRP may promote essential processes in tendon healing including angiogenesis, 
collagen production and accelerate the catabolism of tendinopathic matrix.45 
PLATELET RICH PLASMA AND CHRONIC TENDINOPATHIES  
Evidence for Treating Chronic Tendinopathies with Platelet Rich Plasma Injections 
Over the past decade, there have been numerous experiments aimed at 
determining the efficacy of PRP in treating chronic tendinopathies. From in vitro to 
clinical comparative studies, several aspects of this treatment option have been examined. 
Though studies have produced mixed results, overall researchers believe this therapeutic 
procedure have produced promising findings in its efficacy. 
Laboratory Studies  
Several cell culture studies have been performed in order to support the theory 
that PRP is effective in treating chronic tendinopathies. In an in vitro cell study, Andia 
and colleagues attempted to determine if PRP affects the inflammatory and angiogenic 
levels of tenocytes. After obtaining tendon cells from portions of a degenerative rotator 
cuff tendon, researchers examined its gene expression, modulation and secretion of 
growth factors in a medium containing PRP. The study found evidence that tendinopathic 
tenocytes respond to PRP by downregulating expression of the growth factor interleukin-
1B and increasing the expression of VEGF and hepatocyte growth factor. Based on these 
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findings, investigators concluded that PRP assists degenerative tissue in achieving 
homeostasis under pathological conditions.46,47 
Other studies have focused on whether or not PRP enhances tendon healing by 
promoting the differentiation of tendon stem cells into tenocytes. In a laboratory 
controlled study, Zhang et al measured cell morphology and expression of stem cell 
markers. Using adult rabbit tendon stem cells, cultures that were immersed in a PRP 
medium exhibited high concentrations of active tenocytes and increased levels collagen. 
These results, researchers concluded, suggest that PRP promotes tendon stem cell 
differentiation by increasing proliferation rates. As such, PRP has an anabolic effect on 
tendon stem cells, increasing the number of active tenocytes and concentration of 
collagen thus enhancing wound healing.48,49  
In a similar study, Chen et al used tendon stem cells to compare gene expression 
and healing duration after administration of PRP injections. With saline injections serving 
as the control group, rat diagnosed with Achilles tendinosis were divided into three 
treatment groups: PRP alone, tendon stem cells alone and a combination of the PRP and 
tendon stem cells. Researchers found that tendon stem cells significantly enhanced the 
effects of PRP with higher levels of protein gene expression measured in rats receiving 
the combination therapy. Investigators concluded that the combination therapy had a 
synergistic effect on healing, improving platelet properties in the early phases of 
regeneration and allowing those rats to recover faster.50,51 
Gonzalez and colleagues compared the effects PRP injections have on gene 
expression of Type I collagen, Type III collagen and VEGF in rabbits with Achilles 
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tendinosis over a 12-week period. At week 4, the treatment group exhibited higher rates 
of VEGF expression as well as Type I collagen expression compared to the placebo 
control group. By the end of the study, the PRP group also had higher rates of Type III 
collagen expression. Based on these findings, researchers concluded that PRP have 
regenerative properties in tendon healing.52 
Mechanical Improvements Studies 
Other studies on the efficacy of PRP injections in treating chronic tendinopathies 
focused on whether or not patients exhibited mechanical improvement. For example, 
Wesner and colleagues performed an observational cohort study among athletes. Subjects 
were randomly assigned to either the PRP treatment group or saline treatment group. At 
the 3 month and 6-month post-injection follow-up, investigators noted improved function 
and reduced pain in the PRP injection group when compared to the control group.4 These 
findings are supported by another study conducted by Lyras et al. In 2009, researchers 
applied PRP gel during open surgery for the treatment of patellar tendinopathy. The study 
subjects reported significant improvements in mechanical properties including increased 
range of motion. Investigators hypothesized that such benefits may be attributed to the 
release of platelet growth factors following activation.40 
In a similar study, Sánchez and colleagues conducted a case control study, 
analyzing the outcomes of six athletes who underwent open suture tendon repair in 
addition to application of PRP to the ruptured ends of Achilles tendon. The study 
reported complete recovery of function with no wound complications and athletes 
returning to sporting activities 8 weeks earlier than the control group. Though the sample 
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size of this study is small, investigators suggested that the surgical management of the 
tendon in addition to application of platelet rich growth factor enhances tendon healing.35 
In 2011, Zumstein et al conducted another surgery related study, injecting PRP into 
subjects post-operatively for whom eccentric exercises failed. Once degenerative tissue 
was surgically excised, PRP was injected at the site of injury to promote tendon healing. 
Investigators noted that patients recovered with excellent range of motion and limited 
reported pain.30 
A prospective case series study was conducted by Charousset and colleagues, 
evaluating the clinical outcomes of ultrasound guided PRP injections in athletes 
diagnosed with patellar tendinopathy. Researchers administered three consecutive 
injections at the site of injury and assessed tendon healing one and three months post-
injection. Athletes reported reduced pain and improved function, in which 21 out of 28 
patients recovered to their pre-symptomatic sporting level 3-months after the 
administered therapy. MRI assessment revealed improved structural integrity, further 
supporting clinical outcomes.53  
Kon et al evaluated 20 patients with a history of patellar tendinopathy, also known 
as Jumper's knee, for whom conservative treatments failed. Clinicians injected PRP at the 
site of injury. Patients were also instructed to follow an eccentric exercise program. After 
6 months, 80% of patients reported resuming normal sporting activities. Knee function 
and quality of life improved with little to no complications observed or reported. 
Investigators concluded that PRP in conjunction with physical therapy exercises has the 
potential to reduce pain and allow patients to quicker return to full tendon-loading 
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activities.54 These conclusions are further supported by Filardo and colleagues who also 
evaluated the efficacy of PRP injections in the healing of patellar tendinopathy. Similar to 
Kon et al, investigators concluded that the treatment group had significantly better 
improvements in function, returning to normal sporting activities earlier than the control 
group. Researchers largely attributed the results of their randomized control study to the 
fact that platelets release growth factors, aiding in tendons healing.55,56 In another study 
where other treatment options have failed, Mishra and colleagues investigated the use of 
PRP in treating chronic elbow tendinosis. Out of the 20 evaluated patients, 81% reported 
improvements in function, with a 93% reduction in epicondylar pain. During the Week 8 
evaluations, all patients showed significant reduction in symptoms compared to the 
control group. No complications were noted.57  
Comparisons to Other Treatment Options 
 Several studies compare PRP injections to other treatment options. As discussed 
above, Lyras et al, Zumstein et al and Sánchez et al support the use of either PRP gel 
during surgery or PRP injections post-operatively to enhance tendon healing. 
Arirachakarn and colleagues performed a meta-analysis comparing studies that use PRP 
injections versus steroid injections. Not only did researchers conclude that PRP injections 
reduce tendinopathic pain compared to steroid and other autologous blood injections, but 
also autologous blood injections have the highest risk of complications.58 In 2010, 
Peerbooms et al conducted a study comparing corticosteroid injections to PRP injections. 
In their double-blind randomized study, researchers randomized 100 patients with 
chronic lateral epicondylitis into a treatment PRP group and a corticosteroid control 
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group. Though pain in the corticosteroid group was initially resolved, symptoms returned 
by Week 12 of the study. Conversely, patients in the PRP group progressively improved 
in terms of pain and disability. Investigators concluded that PRP injections are better at 
decreasing pain and increases function than corticosteroid injections in patients with 
tendinosis.59 Martinez-Montiel and colleagues conducted a similar study comparing the 
efficacy of PRP injections to corticosteroid injections. Evaluation one-month post-
injection revealed no significant improvement in terms of pain and function between the 
two groups. However, at the three months follow-up patients reported reduced pain and 
increased function, and at six months this treatment option continued to be more effective 
compared to corticosteroid injections. Researchers concluded that PRP injections have 
prolonged efficacy and is a successful, long-term therapy for chronic tendinopathies.60   
In 2003, Vetrano et al compared the efficacy of PRP injections to electronic shock 
wave therapy (ESWT) in treating athletes diagnosed with Jumper’s knee, or patellar 
tendinosis. In this randomized controlled study, investigators administered two PRP 
injections to the treatment group and three sessions of ESWT to the control group. 
Overall, the study concluded that PRP injections had greater efficacy in treating patellar 
tendinosis, leading to better midterm clinical results in terms of pain management and 
function.61 
Another randomized control study conducted by Dragoo and colleagues compared 
the clinical outcomes of ultrasound guided PRP injections to dry needling in treating 
patellar tendinopathy. Using ultrasound dry needling as the comparison group, in addition 
to both groups following a strict eccentric exercise regimen, researchers reported no 
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adverse effects or treatment failures in the PRP group. Investigators concluded that PRP 
injections not only showed mechanical improvements, but also the recommended 
eccentric exercises in combination with PRP injections accelerated patient’s recovery. 
Nonetheless, the benefits of PRP injections dissipate over time.62 
Other Considerations of Platelet Rich Plasma Injections 
 
Side Effects 
 Patients who have received PRP injections have reported little to no adverse side 
effects, besides moderate pain and stiffness lasting a couple days at the site of 
injection.29,54,63  
Economic Evaluation 
PRP injections are a low-cost, minimally invasive option for treating soft tissue 
injures. In 2006, Navani and colleagues reported that the estimated cost of a single PRP 
treatment is approximately $450, which is significantly more cost effective than surgical 
treatment options. Compared to steroid injections or eccentric exercises, short term costs 
of PRP injections are greater than other therapies.64 However, with greater efficacy and 
decreased need for follow-up injections, PRP injections may prove to be more cost 
effective in the long run.53,65 Nonetheless, a detailed cost-benefit analysis should be 
conducted comparing different treatment options would be beneficial for patients.   
Evidence of Contraindication 
Despite the vast array of studies that support the use of PRP in treating chronic 
tendinopathies, many published reports have refuted its efficacy. In 2010, Schepull et al 
performed a randomized control study to determine if PRP stimulate Achilles tendon 
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healing. Thirty patients underwent surgical repair of Achilles tendon in which PRP was 
injected at proximal and distal locations of the ruptures. Researchers concluded that PRP 
is not useful for treating Achilles tendinopathies noting no significant difference in terms 
of pain or activity improvements between the control and treatment group.66 A 2011 
Platelet Rich Plasma Forum held by the American Academy of Orthopedic Surgeons 
acknowledges that PRP is as a treatment option for musculoskeletal injuries. However, 
the forum determined that its effectiveness still needs to be definitively established.24 
Even though PRP may enhance soft-tissue repair, Dhillon and colleagues concluded that 
this technique may inhibit bone formation as some growth factors, such as PDGF, 
decrease osteoinduction.24 This would be especially problematic for athletes who are 
prone to stress fractures. However, several studies have refuted such findings, claiming 
that the PRP released growth factors aid in bone healing.67 These contradictory findings 
indicate that more research needs to be conducted in analyzing the effect PRP has on 
surrounding tissue. 
Moraes and colleagues assessed the effects platelet rich therapies have in treating 
tendinopathies. Researchers compared clinical outcomes of PRP injections to either a 
placebo, dry needling or autologous blood injections. Since no significant differences 
were reported in terms of pain and function between these groups, investigators 
concluded that there is insufficient evidence to support PRP’s use in treating chronic 
tendinopathies.68 In a similar study, de Vos et al examined if PRP injections improve 
clinical outcomes of patients diagnosed with chronic Achilles tendinopathies. In this 
double blind randomized control trial, researchers compared injections of PRP to that of 
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saline over a 24-week period with both groups following an eccentric exercise regimen. 
No significant differences in clinical outcomes were reported between the two groups.69 
These results are also supported by de Jonge and colleagues’ findings, who evaluated the 
clinical outcomes of patients administered with either PRP or saline injections in 
conjunction with eccentric exercises. Clinical and ultrasonographic analysis also found 
no significant differences between these two groups.70 
In another randomized control trial, Carr et al investigated the clinical outcomes 
of patients diagnosed with rotator cuff tendinopathy who underwent arthroscopic surgery 
and received PRP injections post-operatively. The control group included patients who 
underwent arthroscopic acromioplasty alone, while the treatment group was made up of 
patients who underwent arthroscopic acromioplasty in addition to receiving a PRP 
injection. The study revealed that the combination therapy did not significantly improve 
clinical outcomes. Furthermore, researchers discovered that the injections altered tissue 
characteristics by decreasing vascularity and cell proliferation. Based on these findings, 
the study concluded that PRP injections have a potential deleterious effects on tendon 
healing.71  
 Angiogenesis plays an essential role for wound healing in chronic tendinopathies, 
promoting the recruitment of inflammatory cells and growth factors to the site of injury. 
However, this biological process may also be detrimental to the healing process, altering 
the properties of the extracellular matrix. Angiogenesis significantly enhances the 
expression of matrix metalloproteinases via release of the growth factor, VEGF.72 The 
presence of matrix metalloproteinases, specifically MMP-8 and MMP-9, has been shown 
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to decrease the effectiveness of PRP injections. Additionally, these matrix-degrading 
enzymes release reactive oxygen species, destroying both healthy and injured cells.44,73 
Krishnan and colleagues also concluded that heightened MMP activity as a result of 
angiogenesis, contributes to extracellular matrix dissolution and decreases the stiffness of 
the surrounding area, thereby influencing the tendon’s structural integrity.74 These 
finding suggests that tendon healing may be impaired by angiogenesis.75 
Furthermore, Zang et al concluded that PRP exerts an anti-inflammatory effect on 
degenerative tissues after performing an in vivo culture study. Researchers measured 
levels expression of prostaglandin E2 (PGE2), an inhibitor of platelet aggregation, and 
expressions of COX-1 and COX-2, enzymes that synthesize prostaglandins. Tendon 
cultures containing a PRP medium had a decreased expression and production of PGE2.76 
Additionally, in an animal study performed by Khan and colleagues, investigators 
concluded that repeated exposure of tendon to PGE2 leads to tissue degeneration, 
disrupting the collagen fiber integrity.77 Based on these studies, hindering the production 
of PGE2 via PRP injections would prove to be advantageous in tendon healing. However, 
Riley et al found that PGE2 inhibition results in decreased collagen synthesis and delayed 
tendon healing in their in vitro study, suggesting it plays a positive role in tendon 
remodeling.78,79 These contradictory findings indicate that PGE2 may need to be 
regulated during tendon healing.6 
Other Limitations  
Despite the promising results of in vitro and clinical studies, PRP injections have 
several limitations. One of the most common limitations of PRP injections is the lack of 
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consensus or published reports on how PRP injections should be prepared. Current 
literature on the efficacy of PRP reveal inherent differences in terms of a sample’s 
composition.24 For instance, the concentration of platelets, growth factors and cytokines 
varies from patient to patient. Such inconsistencies are attributable to age, comorbidities 
and healing capabilities, hence affecting the efficacy of treatment.6,26 Additionally, there 
are no published standards for treatment dosage, injection technique, timing of 
centrifugation, method of storage or use of activators or number of injections.24,27 For 
example, though the ideal concentration has yet to be determined, Dhillon and colleagues 
have suggested that platelet concentration need to be a minimum of five times the normal 
serum level in order to enhance wound healing, claiming that platelet concentrations less 
than 1000x106 platelets per milliliter were shown to not enhance wound healing.24 
However, other studies have reported a minimum of 1 million platelets necessary to 
create platelet rich plasma.80 Furthermore, many PRP techniques include leukocytes in 
their injection sample. While leukocytes are essential in immune responses, inclusion of 
white blood cells in a PRP sample may have a deleterious effect on its efficacy. 
Additionally, many PRP centrifugation machines have varying processing times and 
yield different platelet concentrations, therefore influencing the final injection sample 
concentration.4 Finally, the lack of a clear definition and uniformly accepted terminology 
contributes to further confusion, making it difficult to compare studies.30  
CONCLUSION 
Due to advancements in biotechnology, PRP injections have become an 
increasingly popular method in the orthopedic field in treating chronic tendinopathies. 
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Once activated, the concentrated platelet sample is believed to release a myriad of growth 
factors and cytokines at the site of injury, enhancing healing and stimulating cell growth. 
Numerous in vitro studies have supported the rationale behind PRP therapy. From 
increasing tenocyte proliferation to promoting angiogenesis and tenoblast differentiation, 
these platelet-released mediators enhance the healing capability of tendons, augmenting 
the natural healing process and allowing for faster recovery. These effects are maximized 
when administered under ultrasound guidance, providing targeted treatment to the site of 
injury. Furthermore, several patient-centered clinical studies have reported a significant 
improvement in range of motion and pain management compared to traditional injection 
treatments, especially when used in conjunction with a strict eccentric exercise regimen.  
Despite these results, the efficacy of PRP therapy is still a matter of debate. 
Current literature and research on the effectiveness of PRP injections have produced 
contradictory results, which may be due to variations in PRP preparation techniques. 
Some methods add activators such as calcium chloride, while other injections may be 
administered in the presence or absence of leukocytes. Furthermore, since PRP is an 
autologous blood product, platelet concentration differs from patient to patient, 
potentially affecting the efficacy by as much as 50%.7 Such discrepancies in practice and 
administration prompts clinicians to question its efficacy. 
As such, continued research is needed to determine optimal injection standards in 
terms of platelet concentration, preparation techniques and timing of administration. 
Continuing basic science research on the downstream effects of PRP will facilitate 
clinical research, further developing and supporting clinical recommendations and 
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allowing for regulations to be established. A cost-benefit analysis would also be highly 
beneficial for patients when considering treatment option. With limited reported 
complications, low long term costs and fast recovery, PRP injections is a promising, non-
surgical intervention for treating chronic tendinopathies.
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